Market Snapshot

S&P Futures
Dow Futures
NASDAQ Futures

4.99$0.05 1.01%
At close       04:00 PM   

Stock Snapshot

4.94
Prev. Close
4.81
Open
230.79M
Market Cap
2.03M
Number of Shares
4.7800
Day Low
5.1000
Day High
4.99
-
P/E Ratio
-
Free Float in %
-2.31
EPS 2021
0.63
Book Value per Share
1.20
Cash Flow per Share
RedHill Biopharma Ltd. (RDHL)
RedHill Biopharma Ltd. (RDHL) stock rallied over 1.01% intraday to trade at $4.99 share on NASDAQ. The stock opened with a fall of % at $4.81 and touched an intraday high of $5.1000, rising 3.24% against the last close of $4.94. The stock went to a low of $4.7800 during the session.

Historical Data

DateOpenCloseDaily HighDaily LowVolume
2021-09-10$8.91$8.08$9.02$7.97765,710
2021-09-03$9.84$9.49$10.25$9.41122,620,000
2021-09-02$10.24$10.01$10.62$9.80119,920,000
2021-09-01$9.83$10.36$10.45$9.26236,990,000
2021-08-31$9.04$10.10$11.18$9.04984,350,000
2021-08-30$7.91$8.59$8.62$7.81149,450,000
2021-08-27$7.42$7.76$7.99$7.42127,410,000
2021-08-26$7.50$7.29$7.75$6.88290,450,000
2021-08-25$7.56$7.18$7.56$7.1039,290,000
2021-08-24$7.12$7.59$7.65$7.0059,990,000
2021-08-23$6.94$7.09$7.11$6.9232,140,000
RedHill Biopharma Ltd.
21 Ha’arba’a Street
Tel Aviv 6473921
Israel

http://www.redhillbio.com
972 3 541 3131
Employees
155
Sector
Healthcare
Sales or Revenue
84.50M
Industry
Drug Manufacturers - Specialty & Generic
5Y Sales Change
635.00
Fiscal Year Ends
2020-12-30

RedHill Biopharma Ltd.
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focused on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, with a planned Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), a SK2 selective inhibitor targeting various indications with a Phase 2/3 program for COVID-19 and Phase 2 studies for prostate cancer and cholangiocarcinoma ongoing; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and in Phase 2 studies for irritable bowel syndrome with diarrhea; RHB-107, a Phase 2-stage serine protease inhibitor for cancer and inflammatory gastrointestinal diseases, and is also being evaluated for COVID-19; and RHB-106, an encapsulated bowel preparation. The company was founded in 2009 and is headquartered in Tel Aviv, Israel.

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam